$DAAQU

Digital Asset Acquisition Corp. (DAAQU): Entry into a Material Definitive Agreement

Digital Asset Acquisition Corp. (DAAQU) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 CONFIDENTIAL Digital Asset Acquisition Corp. FORM OF NON-REDEMPTION AGREEMENT This NON-REDEMPTION AGREEMENT (this “ Agreement ”), dated as of [●], 2026, is made by and among Digital Asset Acquisition Corp. , a Cayman Islands exempted comp

Original reporting
Published Jun 18, 2026, 9:25 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 18, 2026, 9:29 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$DAAQU
Bullish
medium confidence
Mentioned
$DAAQU
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$DAAQUBullishMed
01

Why it matters

The non-redemption agreement locks in an investor’s commitment not to redeem its shares and sets warrant issuance mechanics after closing, which can improve deal funding certainty.

02

Market read

This is a primary disclosure of investor non-redemption commitments and warrant economics tied to DAAQU’s business combination, relevant to redemption/cash certainty into the vote.

03

What to watch

Traders should verify the specific non-redemption share count on Exhibit A and the exact redemption deadline/conditions in the related business combination agreement, since those drive the real cash impact.

Relevance 6/10Novelty 6/10Timing: after-hours/filing today (8-K filed 2026-06-18) ahead of the redemption deadline and shareholder vote

Background

DAAQU is a Cayman SPAC planning a domestication and merger with Old Glory, with ordinary shares subject to redemption rights ahead of closing.

Company-level read

Ticker impact

$DAAQUBullishMedium confidence
Context

DAAQU filed an 8-K disclosing a non-redemption agreement tied to its business combination, including issuance of non-redemption warrants post-closing.

Expected impact

Likely supportive for deal-close probability and near-term sentiment versus a redemption-heavy outcome.

Evidence & confidence

The filing is a primary SEC disclosure of investor behavior (non-redemption) and warrant economics, which can materially affect SPAC cash/redemption dynamics and perceived closing odds.

Market effects

Adds another datapoint on SPAC-style redemption management via investor non-redemption commitments and warrant incentives.

Limited; primarily affects Nasdaq-listed SPAC/blank-check sentiment.

Low; deal mechanics are company-specific.

Counterpoint

Non-redemption agreements may not fully eliminate redemption risk if other holders redeem heavily or if deal conditions fail.

Key entities

  • Digital Asset Acquisition Corp. (DAAQU)

    Cayman exempted company entering a material definitive agreement via an 8-K; subject of the filing.

  • Old Glory Holding Company

    Delaware bank holding company that will merge into the company upon closing.

  • Investor (counterparty to non-redemption agreement)

    Agrees to non-redemption of specified shares and receives non-redemption warrants post-closing.

Related articles

$MPLTMedAI 8/10

MapLight Raises $150 M PIPE To Fund CNS Pipeline

MapLight Therapeutics (MPLT) priced a $150 million PIPE, selling 9.2M shares at $11.38 and 4.0M pre-funded warrants at $11.3799, exercisable at $0.0001 with no expiration. Proceeds will fund CNS drug ML-007C-MA, including VISTA Phase 2 in Alzheimer’s disease psychosis and ZEPHYR-2 Phase 3 in schizophrenia. Closing expected Aug. 14, 2026.

$TSNMedAI 8/10

Tyson Foods will close or sell three US beef facilities as industry struggles

Tyson Foods said it will close or sell three US beef facilities, ending operations at Joslin, Illinois and Eagle Mountain, Utah, and pursuing the sale of Pasco, Washington, while shifting capacity to other sites. The move follows prior Tyson beef shutdowns and comes as a 75-year cattle supply trough drives losses. Tyson forecast a $500m to $650m adjusted beef operating loss for fiscal 2026.

$MVISMedAI 8/10

MicroVision, Inc.: MicroVision Announces Launch of Proposed Public Offering

MicroVision (NASDAQ:MVIS) said it has commenced a proposed public offering of units, each unit consisting of one share of common stock (or a pre-funded warrant in lieu) and one warrant to buy one share. MicroVision will sell the shares and warrants, with final terms to be set at pricing. Net proceeds are for general corporate purposes, including working capital and capex.

$ORCLMed

Oracle planning new round of layoffs in August 2026

Oracle plans another layoff round in August 2026, according to Business Insider citing internal documents and people familiar with the plans. It says some teams could face double-digit cuts, with managers asked to identify affected employees ahead of Sept. 1. Oracle previously cut 21,000 jobs and recorded $1.8B restructuring charges. Oracle is funding AI data centers with large debt and equity.

$TSNMed

Tyson Foods to close 2 facilities, pursue sale of another amid 'historic' cattle shortage

Tyson Foods said it will close its Joslin, Illinois beef plant and its Eagle Mountain, Utah case-ready facility, and is pursuing the sale of its Pasco, Washington beef facility, citing strategic changes to its beef network amid a “historic” cattle shortage. Tyson plans to shift capacity to Dakota City, Nebraska; Holcomb, Kansas; and Amarillo, Texas, and ramp a second shift in Amarillo, according to the company.

$KPTIHighAI 9/10

It's crunch time for Karyopharm as company faces potential default next month

Karyopharm Therapeutics reported Q2 results showing a $67 million loss and cash reserves of $65.4 million. A $15.8 million loan payment is due Sept. 10, and without financing or a waiver the company says it would breach a $10.0 million liquidity covenant and could default. It is negotiating with lenders and pursuing Xpovio label expansion; Q2 Xpovio sales were $30.8 million.